Drug Interactions between eliglustat and Votrient
This report displays the potential drug interactions for the following 2 drugs:
- eliglustat
- Votrient (pazopanib)
Interactions between your drugs
PAZOPanib eliglustat
Applies to: Votrient (pazopanib) and eliglustat
Before using eliglustat, you should have received a test to determine your CYP450 2D6 genotype, which lets the doctor know whether or not you can take the medication and at what dosage. Depending on your CYP450 2D6 genotype and what other medications you may be on, using eliglustat together with PAZOPanib may not be recommended at all, or a dosage adjustment of eliglustat may be needed. Treatment with PAZOPanib can increase the blood levels of eliglustat. This may increase the risk of serious and potentially life-threatening cardiac side effects such as irregular heart rhythm, heart block, and cardiac arrest. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the interaction, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, slow heart rate, weak pulse, or heart palpitations during treatment with eliglustat. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
PAZOPanib food
Applies to: Votrient (pazopanib)
Do not consume grapefruit or grapefruit juice during treatment with PAZOPanib unless directed otherwise by your doctor. Grapefruit juice can increase the blood levels of PAZOPanib, which may lead to an increased risk of serious side effects such as liver damage, irregular heart rhythm, bleeding, high blood pressure, heart attack, and stroke. Taking PAZOPanib with food can also significantly increase its absorption and levels in the blood. Therefore, you should take PAZOPanib on an empty stomach, at least one hour before or two hours after eating. Call your doctor immediately if you develop fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, dark colored urine, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. You should also seek immediate medical attention if you experience signs and symptoms that could indicate cardiovascular problems such as sudden dizziness; lightheadedness; fainting; fast or pounding heartbeats; chest pain or tightness; pain in your arms, back, neck, or jaw; shortness of breath; numbness or weakness on one side of your body; and slurred speech or difficulty speaking. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
eliglustat food
Applies to: eliglustat
Do not consume grapefruit or grapefruit juice during treatment with eliglustat unless directed otherwise by your doctor. Grapefruit juice can increase the blood levels of eliglustat to dangerous levels. This may increase the risk of serious and potentially life-threatening cardiac side effects such as irregular heart rhythm, heart block, and cardiac arrest. Talk to your doctor if you have any questions or concerns. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, slow heart rate, weak pulse, or heart palpitations during treatment. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.